Pedro Cuatrecasas
From Wikipedia, the free encyclopedia
Pedro Cuatrecasas (1936) is an American biochemist and an Adjunct Professor of Pharmacology & Medicine at the University of California, San Diego.[1]
Contents |
[edit] Birth and education
Pedro Cuatrecasas was born in 1936 in Madrid, Spain. He completed his A.B. from Washington University in St. Louis in 1958. After completing his undergraduate, he completed his M.D. from the same university in 1962.
[edit] Research
Pedro Cuatrecasas is known for the invention and development of affinity chromatography, a process utilized within the Aethlon HemopurifierTM. He was involved in the discovery, development and marketing registration of more than forty medicines. Some of those medicins include: zidovudine (AZT, AIDS), acyclovir (Zovirax, anti-herpes), permethrin (Rid, head and body lice), bupropion (Wellbutrin, antidepressant), calsfosceril (Exosurf, infant acute respiratory distress), remifentanil (Ultiva, analgesic/anesthetic), sumatriptan (Imigran, migraine), salmeterol (Serement, asthma), tacrine (Cognex, Alzheimers), gabapentin (Neurontin, epilepsy and neuropathic pain), troglitazone (Rezulin, diabetes), and atorvastatin (Lipitor, cholesterol lowering).
In 1987 Pedro Cuatrecasas won the Wolf Prize in Medicine in 1987 along with Meir Wilchek "for the invention and development of affinity chromatography and its applications to biomedical sciences."[2]
[edit] References
[edit] External links
- CV of Pedro Cuatrecasas
- Researchers Share Prize in Medicine
- The Wolf Prize in Medicine in 1987 (detail)
